Literature DB >> 20801068

Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy.

Nina Raben1, Evelyn Ralston, Yin-Hsiu Chien, Rebecca Baum, Cynthia Schreiner, Wuh-Liang Hwu, Kristien J M Zaal, Paul H Plotz.   

Abstract

Pompe disease is a lysosomal storage disorder caused by the deficiency of acid alpha-glucosidase, the enzyme that degrades glycogen in the lysosomes. The disease manifests as a fatal cardiomyopathy and skeletal muscle myopathy in infants; in milder late-onset forms skeletal muscle is the major tissue affected. We have previously demonstrated that autophagic inclusions in muscle are prominent in adult patients and the mouse model. In this study we have evaluated the contribution of the autophagic pathology in infants before and 6 months after enzyme replacement therapy. Single muscle fibers, isolated from muscle biopsies, were stained for autophagosomal and lysosomal markers and analyzed by confocal microscopy. In addition, unstained bundles of fixed muscles were analyzed by second harmonic imaging. Unexpectedly, the autophagic component which is so prominent in juvenile and adult patients was negligible in infants; instead, the overwhelming characteristic was the presence of hugely expanded lysosomes. After 6 months on therapy, however, the autophagic buildup becomes visible as if unmasked by the clearance of glycogen. In most fibers, the two pathologies did not seem to coexist. These data point to the possibility of differences in the pathogenesis of Pompe disease in infants and adults.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20801068      PMCID: PMC2991562          DOI: 10.1016/j.ymgme.2010.08.001

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  35 in total

1.  LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.

Authors:  Y Kabeya; N Mizushima; T Ueno; A Yamamoto; T Kirisako; T Noda; E Kominami; Y Ohsumi; T Yoshimori
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

Review 2.  Autophagy fights disease through cellular self-digestion.

Authors:  Noboru Mizushima; Beth Levine; Ana Maria Cuervo; Daniel J Klionsky
Journal:  Nature       Date:  2008-02-28       Impact factor: 49.962

3.  Monitoring autophagy in lysosomal storage disorders.

Authors:  Nina Raben; Lauren Shea; Victoria Hill; Paul Plotz
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

Review 4.  Autophagy revisited: a conversation with Christian de Duve.

Authors:  Daniel J Klionsky
Journal:  Autophagy       Date:  2008-06-09       Impact factor: 16.016

5.  A randomized study of alglucosidase alfa in late-onset Pompe's disease.

Authors:  Ans T van der Ploeg; Paula R Clemens; Deyanira Corzo; Diana M Escolar; Julaine Florence; Geert Jan Groeneveld; Serge Herson; Priya S Kishnani; Pascal Laforet; Stephen L Lake; Dale J Lange; Robert T Leshner; Jill E Mayhew; Claire Morgan; Kenkichi Nozaki; Dorothy J Park; Alan Pestronk; Barry Rosenbloom; Alison Skrinar; Carine I van Capelle; Nadine A van der Beek; Melissa Wasserstein; Sasa A Zivkovic
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

6.  Identification of eight novel mutations of the acid alpha-glucosidase gene causing the infantile or juvenile form of glycogen storage disease type II.

Authors:  L Wan; C-C Lee; C-M Hsu; W-L Hwu; C-C Yang; C-H Tsai; F-J Tsai
Journal:  J Neurol       Date:  2008-05-06       Impact factor: 4.849

7.  Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand...

Authors:  Nina Raben; Shoichi Takikita; Maria G Pittis; Bruno Bembi; Suely K N Marie; Ashley Roberts; Laura Page; Priya S Kishnani; Benedikt G H Schoser; Yin-Hsiu Chien; Evelyn Ralston; Kanneboyina Nagaraju; Paul H Plotz
Journal:  Autophagy       Date:  2007-06-15       Impact factor: 16.016

8.  Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program.

Authors:  Yin-Hsiu Chien; Shu-Chuan Chiang; Xiaokui Kate Zhang; Joan Keutzer; Ni-Chung Lee; Ai-Chu Huang; Chun-An Chen; Mei-Hwan Wu; Pei-Hsin Huang; Fu-Jen Tsai; Yuan-Tsong Chen; Wuh-Liang Hwu
Journal:  Pediatrics       Date:  2008-06-02       Impact factor: 7.124

9.  Detection and imaging of non-contractile inclusions and sarcomeric anomalies in skeletal muscle by second harmonic generation combined with two-photon excited fluorescence.

Authors:  E Ralston; B Swaim; M Czapiga; W-L Hwu; Y-H Chien; M G Pittis; B Bembi; O Schwartz; P Plotz; N Raben
Journal:  J Struct Biol       Date:  2008-04-08       Impact factor: 2.867

Review 10.  Therapeutic approaches in glycogen storage disease type II/Pompe Disease.

Authors:  Benedikt Schoser; Victoria Hill; Nina Raben
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

View more
  27 in total

1.  36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy.

Authors:  Caroline Regnery; Cornelia Kornblum; Frank Hanisch; Stefan Vielhaber; Nicola Strigl-Pill; Birgit Grunert; Wolfgang Müller-Felber; Franz Xaver Glocker; Matthias Spranger; Marcus Deschauer; Eugen Mengel; Benedikt Schoser
Journal:  J Inherit Metab Dis       Date:  2012-01-31       Impact factor: 4.982

Review 2.  Enzyme replacement therapy for Pompe disease.

Authors:  Corrado Angelini; Claudio Semplicini
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

Review 3.  Challenges in treating Pompe disease: an industry perspective.

Authors:  Hung V Do; Richie Khanna; Russell Gotschall
Journal:  Ann Transl Med       Date:  2019-07

4.  Muscle fiber-type distribution, fiber-type-specific damage, and the Pompe disease phenotype.

Authors:  L E M van den Berg; M R Drost; G Schaart; J de Laat; P A van Doorn; A T van der Ploeg; A J J Reuser
Journal:  J Inherit Metab Dis       Date:  2012-10-11       Impact factor: 4.982

5.  Improved efficacy of a next-generation ERT in murine Pompe disease.

Authors:  Su Xu; Yi Lun; Michelle Frascella; Anadina Garcia; Rebecca Soska; Anju Nair; Abdul S Ponery; Adriane Schilling; Jessie Feng; Steven Tuske; Maria Cecilia Della Valle; José A Martina; Evelyn Ralston; Russell Gotschall; Kenneth J Valenzano; Rosa Puertollano; Hung V Do; Nina Raben; Richie Khanna
Journal:  JCI Insight       Date:  2019-03-07

Review 6.  Engineered skeletal muscles for disease modeling and drug discovery.

Authors:  Jason Wang; Alastair Khodabukus; Lingjun Rao; Keith Vandusen; Nadia Abutaleb; Nenad Bursac
Journal:  Biomaterials       Date:  2019-08-08       Impact factor: 12.479

Review 7.  Long-term outcome and unmet needs in infantile-onset Pompe disease.

Authors:  Andreas Hahn; Anne Schänzer
Journal:  Ann Transl Med       Date:  2019-07

Review 8.  Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten.

Authors:  Nina Raben; Amanda Wong; Evelyn Ralston; Rachel Myerowitz
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-01-17       Impact factor: 3.908

9.  Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Kunil K Raval; Ran Tao; Brent E White; Willem J De Lange; Chad H Koonce; Junying Yu; Priya S Kishnani; James A Thomson; Deane F Mosher; John C Ralphe; Timothy J Kamp
Journal:  J Biol Chem       Date:  2014-12-08       Impact factor: 5.157

10.  Quantitative evaluation of skeletal muscle defects in second harmonic generation images.

Authors:  Wenhua Liu; Nina Raben; Evelyn Ralston
Journal:  J Biomed Opt       Date:  2013-02       Impact factor: 3.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.